Deal Watch: Roche Returns To RNAi With Santaris Buyout, While Biogen Re-Ups With Regulus
Executive Summary
Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.